Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 07.12.2018 | 07:00

Carl Zeiss Meditec continues on growth course in fiscal year 2017/18

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Annual Results

07.12.2018 / 07:00
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec continues on growth course in fiscal year 2017/18
 
Both strategic business units make good contributions / Significant increases in Americas and APAC regions
 

JENA, 7 December 2018

Carl Zeiss Meditec AG increased its revenue further in all strategic business units and regions after twelve months of fiscal year 2017/18. Revenue increased by 7.6 percent (adjusted for currency effects: 11.1 percent), to EUR1,280.9m (prior year: EUR1,189.9m). Earnings before interest and taxes (EBIT) rose to EUR197.1m (prior year: EUR180.8m). The EBIT margin remained stable at 15.4 percent (prior year: 15.2 percent). Earnings per share reached EUR1.41 (prior year: EUR1.57).
 

"We achieved our sales forecast, which we had already raised in July 2018 - in spite of negative currency effects. In fiscal year 2017/18 we gained further market shares in both ophthalmology and microsurgery. What is particularly encouraging is that all regions and business segments contributed - the performance of the Americas and Asia/Pacific regions was particularly strong," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
 

Solid growth and market share gains in both strategic business units

The strategic business unit (SBU) Ophthalmic Devices increased its revenue by 6.0 percent after twelve months of fiscal year 2017/18 (adjusted for currency effects: 9.3 percent), to EUR933.3m, compared with EUR880.5m in the same period of the prior year. The laser systems business for vision correction and the diagnostics business developed particularly well. There was also continued solid demand for premium and standard intraocular lenses for the treatment of cataracts.

Revenue in the Microsurgery SBU grew by 12.3 percent (adjusted for currency effects: 16.5 percent), to EUR347.6m, compared with EUR309.4 in the prior year. This growth is particularly attributable to the new products for the neurosurgery and dental segments.

 

Significant growth, particularly in Americas and APAC regions

Revenue in the EMEA region increased by 4.0 percent (adjusted for currency effects: 5.4 percent), to EUR378.1m (prior year: EUR363.4m). Development in the core markets Germany and France was stable. Increases were achieved in the UK, Southern Europe and some Eastern European markets.

A positive trend was also recorded in the Americas region. Revenue increased to EUR406.5m (prior year: EUR378.2m). This growth amounted to 7.5 percent (adjusted for currency effects: 14.4 percent) and thus accelerated significantly compared with the prior year. This is primarily due to a continued positive trend in the U.S. market.

The Asia/Pacific (APAC) region grew by 10.7 percent, to EUR496.3m (prior year: EUR448.2m). After adjustment for currency effects, this corresponds to an increase of 13.2 percent. Once again, the largest contributions to growth came from China and South Korea.

The EBIT margin was 15.4 percent (prior year: 15.2 percent). Adjusted for special effects, an increase to 15.7 percent was recorded (prior year: 14.8 percent). This was due in particular to a positive development of the product mix. Revenue from recurring business, such as from consumables, implants and services, increased further, and climbed to around 34 percent of revenue (prior year: 33 percent).

Earnings per share declined slightly, to EUR1.41 (prior year: EUR1.57). This decrease was attributable to negative currency effects and to the increased number of shares.

Carl Zeiss Meditec AG anticipates further growth for fiscal year 2018/19, at least to the level of the underlying markets. The EBIT margin is expected to range between 14 percent and 16 percent in fiscal year 2018/19 and in the medium term.
 

Revenue by strategic business unit

All figures in EURm 12 months 2017/18 12 months 2016/17 Change from prior year Change from prior year (adjusted for currency effects)
Ophthalmic Devices 933.3 880.5 +6.0% +9.3%
Microsurgery 347.6 309.4 +12.3% +16.5%
Total 1,280.9 1,189.9 +7.6% +11.1%
 

 

Revenue by region

All figures in EURm 12 Months 2017/18 12 Months 2016/17 Change from prior year Change from prior year (adjusted for currency effects)
EMEA 378.1 363.4 +4.0% +5.4%
Americas 406.5 378.2 +7.5% +14.4%
APAC 496.3 448.2 +10.7% +13.2%
Total 1,280.9 1,189.9 +7.6% +11.1%
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.com

 



07.12.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Technologiespezialist Hörmann Industries begibt 50 Mio. Euro-Anleihe – Mindestzinssatz von 4,5% p.a.

Die Hörmann Industries GmbH begibt eine neue Unternehmensanleihe mit einem Volumen von bis zu 50 Millionen Euro. Die neue Anleihe der Technologiespezialisten aus Oberbayern (ISIN: NO0010851728 / WKN: A2TSCH) wird im sogenannten Nordic Bond-Format begeben und unterliegt norwegischem Recht.


ISIN: NO0010851728
Stückelung: 1.000 Euro
Zeichnungsmöglichkeit: Börse Frankfurt, über die Haus- oder Direktbank
Mindestzinssatz: 4,500 %
Zinssatz (Kupon) p.a.: Bekanntgabe spätestens nach Ende des Angebotszeitraums,voraussichtlich am 28. Mai 2019
Laufzeit: 5 Jahre

Interview im Fokus

„Das Globalmatix-Geschäft wird hochprofitabel“

Durchbruch für Globalmatix: Die Tochter der Softing AG hat mit dem Gewinn eines Großkunden einen wichtigen Meilenstein erreicht. „Wir sehen sehr gute Chancen, bei laufenden Ausschreibungen weitere Erfolge zu feiern“, zeigt sich Softing-CEO Dr. Trier optimistisch. Die hohe Skalierbarkeit soll Softing dem Ziel einer zweistelligen EBIT-Marge näherbringen. Die Prognose für 2019 sieht Dr. Trier angesichts des starken Auftragsbestands als konservativ.

Event im Fokus

m:access Fachkonferenz Immobilien
m:access Fachkonferenz Software/IT


04. Juni 2019: m:access Fachkonferenz Immobilien
05. Juni 2019: m:access Fachkonferenz Software/IT
Veranstaltungsort: Börse München
Mehr Informationen

Zur Veranstaltung können sich nur professionelle Investoren anmelden.

GBC-Fokusbox

Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance

Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.

News im Fokus

Vonovia SE: Vonovia beantragt Squeeze-out-Verfahren zum Erwerb der Minderheitenanteile an Victoria Park (News mit Zusatzmaterial)

24. Mai 2019, 09:05

Aktueller Webcast

ADO Properties S.A.

Dreimonats-
Investor Call
Q1 2019

22. Mai 2019

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): Halten

24. Mai 2019